Latest News and Press Releases

- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL®...

HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...

Abaxx Technologies and Alta announce commercial engagement to advance the use of money market fund shares as T+0 collateral for margin at Abaxx Clearing

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on...

SONATA-HCM anticipated to be fully enrolled mid-2026  Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851...

Harvard Bioscience to Participate in Upcoming Investor Conferences

TROY, Mich., May 07, 2026 (GLOBE NEWSWIRE) -- Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the first quarter of 2026. Q1 revenue of $1.0...

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- QuasarEdge Acquisition Corporation (NYSE: QRED, “QuasarEdge”), a Cayman Islands exempted company formed as a special purpose acquisition company, today...

COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business...

, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in...